Balyasny Asset Management
PDSB icon

Balyasny Asset Management’s PDS Biotechnology PDSB Stock Holding History

Balyasny Asset Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,802
Closed -$128K – 2755
2021
Q4 		$128K Buy
+15,802
New +$170K ﹤0.01% 1929

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Balyasny Asset Management's PDSB Position: Q1 2022 in Review

Balyasny Asset Management sold out of PDS Biotechnology (PDSB) in Q1 2022, closing a stake of 15,802 shares — an estimated $128K sold.

Balyasny Asset Management first reported a position in PDSB in Q4 2021 and held it in 1 quarter. The position peaked at $128K in Q4 2021. 52 funds tracked by Wall St. Rank hold PDSB as of Q1 2022.

  • Balyasny Asset Management reported no remaining PDS Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 15,802 PDS Biotechnology shares in Q1 2022, an estimated $128K.
  • Balyasny Asset Management first reported a position in PDS Biotechnology in Q4 2021 and held it in 1 quarter.
  • Balyasny Asset Management's PDS Biotechnology position peaked at $128K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2022.

Based on Balyasny Asset Management's 13F filing for Q1 2022, filed 16 May 2022.